Advertisement

Cellular and Molecular Life Sciences

, Volume 67, Issue 9, pp 1559–1560 | Cite as

Angiostasis-induced vascular normalization can improve photodynamic therapy

  • Patrycja Nowak-Sliwinska
  • Georges Wagnières
  • Hubert van den Bergh
  • Arjan W. Griffioen
Letters and Comments

In a recent issue, Cellular and Molecular Life Sciences published on the combination of photodynamic therapy (PDT) and anti-angiogenesis for the treatment of cancer [1]. In this paper, Bhuvaneswari and colleagues elegantly review this field. The idea behind combining these two therapeutic strategies is based on the observation that PDT can lead to vessel closure, and hence hypoxia, as well as other tissue damage resulting in inflammation. This combination of hypoxia and inflammation can in turn cause the enhanced release of angiogenic growth factors (vascular endothelial growth factor, VEGF) followed by the regrowth of the targeted neoplastic tissue. Thus, it appeared logical to try to block the VEGF pathways after PDT, for instance by applying antibodies against VEGF. This type of combination therapy is not limited to the treatment of cancer. Indeed, for the treatment of certain forms of exudative macular degeneration, recently published results from a phase II clinical study...

Keywords

Angiogenesis Inhibitor Drug Cocktail Lucentis Vascular Normalization Improve Visual Acuity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci 66:2275–2283CrossRefPubMedGoogle Scholar
  2. 2.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMedGoogle Scholar
  3. 3.
    Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–3402CrossRefPubMedGoogle Scholar
  4. 4.
    Sagong M, Lee J, Chang W (2009) Application of intravitreal bevacizumab for circumscribed choroidal hemangioma. Korean J Ophthalmol 23:127–131CrossRefPubMedGoogle Scholar
  5. 5.
    Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T (2006) A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 66:10953–10958CrossRefPubMedGoogle Scholar
  6. 6.
    Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475–485CrossRefPubMedGoogle Scholar
  7. 7.
    Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR (2008) Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 14:3124–3131CrossRefPubMedGoogle Scholar
  8. 8.
    Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM (2008) Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci USA 105:5105–5110CrossRefPubMedGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  • Patrycja Nowak-Sliwinska
    • 1
  • Georges Wagnières
    • 1
  • Hubert van den Bergh
    • 1
  • Arjan W. Griffioen
    • 2
  1. 1.Medical Photonics Group, Institute of Bioengineering, Institute of Chemical Sciences and EngineeringSwiss Federal Institute of Technology (EPFL)LausanneSwitzerland
  2. 2.Angiogenesis Laboratory, Department of Medical OncologyVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations